Psoriasis

Long-term Data Suggests Deucravacitinib Safe, Effective for Treating Plaque Psoriasis

May 12, 2022

Data from the POETYK PSO long-term extension (LTE) trial showed deucravacitinib was clinically effective and safe for treating adult patients with moderate-to-severe plaque psoriasis.

Jeffrey Stark, MD: Latest Bimekizumab Data for Treatment of Psoriatic Arthritis, Psoriasis

April 26, 2022

Jeffrey Stark, MD, discusses the latest bimekizumab and certolizumab pegol data presented at the 2022 American Academy of Dermatology annual meeting.

Deucravacitinib Effectively Treats Moderate-to-Severe Plaque Psoriasis

January 20, 2022

Deucravacitinib selectively binds to a unique pocket in the regulatory domain of TYK2 instead of the highly conserved active site of the catalytic domain,” investigators explained. “This leads to targeted inhibition of immune pathways that are central to psoriasis while limiting off-target effects.”

Jeffrey Stark, MD: Safety and Efficacy of Bimekizumab as Psoriasis Treatment

October 18, 2021

Jeffrey Stark, MD, discusses the recent studies, BE BRIGHT, BE SURE, and BE VIVID, in which investigators analyzed the impact bimekizumab had on patients with psoriasis.

Guselkumab Sustained Long-Term Efficacy in Patients with Active Psoriatic Arthritis

March 18, 2021

Guselkumab is the first and only approved IL-23 inhibitor therapy used to treat adults with active PsA and moderate to severe plaque psoriasis (PsO). The medication showed efficacy in skin clearance and joint symptom relief and passed safety measures. Additionally, physical function, health-related quality of life, and resolution of enthesitis and dactylitis were confirmed through week 100.

Secukinumab Not Associated With Tuberculosis

October 02, 2020

Researchers writing in JAMA Dermatology report that latent tuberculosis infection previously assumed to be an adverse event as a result of treatment with secukinumab, is actually uncommon in patients with chronic systemic inflammatory conditions.

Psoriasis Risk Rises with TNF Inhibitor Use in Pediatric Inflammatory Diseases

November 27, 2019

Children with inflammatory bowel disease, juvenile idiopathic arthritis, and chronic noninfectious osteomyelitis who were treated with TNF inhibitors had a higher rate of incident psoriasis than those not exposed to these biologics, say researchers recently writing in Arthritis Care & Research.